about
Exploiting tumor epigenetics to improve oncolytic virotherapyMultimodal regulation of E2F1 gene expression by progestinsEpigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancersFoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcriptionCell-type selective chromatin remodeling defines the active subset of FOXA1-bound enhancersCistromics of hormone-dependent cancerBioID identifies novel c-MYC interacting partners in cultured cells and xenograft tumorsLaying a solid foundation for Manhattan--'setting the functional basis for the post-GWAS era'.Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid TumorsChromatin profiling reveals regulatory network shifts and a protective role for hepatocyte nuclear factor 4α during colitis.PBX1 genomic pioneer function drives ERα signaling underlying progression in breast cancer.Nucleosome dynamics define transcriptional enhancers.Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistanceEpigenomic alterations define lethal CIMP-positive ependymomas of infancyIdentification of PBX1 target genes in cancer cells by global mapping of PBX1 binding sites.Human-chromatin-related protein interactions identify a demethylase complex required for chromosome segregation.Genomic collaboration of estrogen receptor alpha and extracellular signal-regulated kinase 2 in regulating gene and proliferation programs.Enhancer alterations in cancer: a source for a cell identity crisis.Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.ZNF143 provides sequence specificity to secure chromatin interactions at gene promoters.ABC: a tool to identify SNVs causing allele-specific transcription factor binding from ChIP-Seq experiments.Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expressionDual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.A comprehensive view of nuclear receptor cancer cistromesBlockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.Unique ERalpha cistromes control cell type-specific gene regulationPre-neoplastic epigenetic disruption of transcriptional enhancers in chronic inflammation.Coactivator function defines the active estrogen receptor alpha cistrome.Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer.Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway.Layers of epistasis: genome-wide regulatory networks and network approaches to genome-wide association studies.Chromatin landscape and endocrine response in breast cancer.Chromatin and epigenetic determinants of estrogen receptor alpha (ESR1) signaling.A global assessment of cancer genomic alterations in epigenetic mechanisms.TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer.Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer.PharmacoGx: an R package for analysis of large pharmacogenomic datasets.Personalized diagnosis of medulloblastoma subtypes across patients and model systems.
P50
Q21131237-CB3F1BA9-6571-4B06-95D1-5BEB00251F77Q24604986-B0F28E1C-D98D-4B5D-A494-F396D3E5E4E8Q24630926-826E54A6-6749-47C1-9C60-911E1B55228CQ24645118-02FDAA07-D1AD-4F0E-AA7A-AD9728AE82B8Q24651915-F5A70140-84DF-488E-AE91-D0AD59260FC0Q28241427-BCAD26FF-9954-483F-BAA5-AF90E4B04FF1Q28252738-60FEEF37-433D-4366-BFC0-541F5FC22CF6Q33631309-B6A75A5A-19D1-466E-8BFB-A6C49C562870Q33882326-D13584D6-DFCB-4C51-AFF7-7F1E1B7C745CQ34056411-1A469394-377F-47A8-A51C-D0404ED978E9Q34085622-39A5CBD1-B2D3-4CDE-A311-E9AB914D5FE0Q34099759-DAC65BCA-4C1E-422D-B2AE-E131D353CF9AQ34164930-B9D912B9-BBF0-468A-AF8C-063A4490A793Q34240198-253E4ED2-BF46-4D7E-9C07-F45D076B5A60Q34261669-2419DB8D-63E4-47D5-A64E-F50B165FB16AQ34427234-B5A08AC2-7D74-46CB-A14B-8D22E8AC8BAFQ34484372-307F9807-AEBC-402B-B27D-7A74023B53BBQ34624854-4667844D-68DD-4546-BAA9-7D0E63260960Q34775924-FE4C88AF-8B12-4E59-969D-8EE943A488B9Q35064451-69A75235-4F59-438A-8EC8-4AD5F847DF15Q35606351-864A459E-F071-4DBE-87DB-93421F9DB5C6Q36344543-8C1E3C5B-F15C-405E-A8B3-3C4206A1B903Q36354441-3AB02354-AF82-442E-B904-699C92513DE9Q36376583-2232CDC8-3BED-4B4C-99C8-1B343BC9B348Q36723842-743F4C06-9CAC-4DDA-9EA6-45E560AB5C04Q36902056-0086B31D-B002-4CE2-9D92-67D6E5EDF0A0Q36971843-CED1D605-F600-48B9-B320-ECFECD7AA59AQ37085879-D71A8A35-EDAF-4CB8-8BEA-5278574AC4F5Q37233367-FD00FED3-E8C1-4B69-AA1C-F37F5571D997Q37297706-197F5904-9CE3-4BE4-A75E-597F140CA9C4Q37305014-55AF8F2E-39B3-465E-AF73-084C4DE02640Q37674501-ADE88F11-5D07-4EFB-A037-B3C7C4162DBDQ37825463-6A3C25D6-36A6-4D77-AC06-7E69A868A4DCQ38067765-9E9D5E28-BC5A-4E98-91DF-95E919ED98F1Q38107711-8787583D-A04F-400B-BE0D-D29ECFA067E4Q38446450-EB3E9E6E-8CB6-41C6-82E9-4D59291AFBA5Q38637158-7FCBD751-2C84-4B67-BC88-E6307DD6A739Q38751776-2A657CA2-D5A7-4DFC-9B4C-434F150B0C8DQ38812641-B7B7B38C-45AD-4988-A7E1-DE5564A311E2Q38874298-5A63CE58-2163-4904-95EB-146487B7A728
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mathieu Lupien
@ast
Mathieu Lupien
@en
Mathieu Lupien
@es
Mathieu Lupien
@nl
Mathieu Lupien
@sl
type
label
Mathieu Lupien
@ast
Mathieu Lupien
@en
Mathieu Lupien
@es
Mathieu Lupien
@nl
Mathieu Lupien
@sl
prefLabel
Mathieu Lupien
@ast
Mathieu Lupien
@en
Mathieu Lupien
@es
Mathieu Lupien
@nl
Mathieu Lupien
@sl
P106
P1153
23501997200
P21
P2456
P31
P496
0000-0003-0929-9478